Trial
NCT02952989
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Seagen Inc.
Collaborators
—
Condition
Carcinoma, Non-Small-Cell Lung
Intervention
SGN-2FF
Why stopped
Due to overall benefit/risk profile
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-07-19